AC Immune

ACIU

Market cap $306M

AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphomer candidates and boosting long-term Alzheimer's strategy.

Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this year.

This will help fund the biotech's development of a unique treatment for neurodegenerative diseases like Alzheimer's. The company could earn more than $2.1 billion if this work is successful.

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significant progress made with our Morphomer small molecules Investigational New Drug (IND)-enabling studies to commence in H1 2026 Lausanne, Switzerland, April 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced an agreement with Eli Lilly and Company (Lilly) to amend their 2018 license and collaboration agreement to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease (AD) and other neurodegenerative diseases. The amendment continues the research and collaboration to cover development of new lead Tau Morphomer® candidates and potential back-up compounds.

AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here is how AC Immune (ACIU) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's disease NLRP3 inhibitor ACI-19764 Phase 1 trial initiated with first participants dosed Approaching multiple value-inflection points, including interim results of the AD3 cohort in the Phase 2 ABATE trial of ACI-24 in Alzheimer's disease in H1 2026, and full 24-month data from Part 1 of the Phase 2 VacSYn trial of ACI-7104 in Q3 2026 Cash resources of CHF 91.4 million as of December 31, 2025, provide funding to the end of Q3 2027 before any potential milestone payments Lausanne, Switzerland, March 13, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, 2025, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress towards delivering precision prevention of neurodegenerative diseases in 2025, exemplified by the exceptional interim data from the VacSYn trial of ACI-7104, our wholly-owned active immunotherapy targeting α-synuclein.

AC Immune receives a "Buy" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's Disease. AC Immune is advancing ACI-7104.056, with upcoming FDA discussions to potentially establish a registration study as a key value-driving catalyst. The company benefits from a robust pipeline, including partnerships with Takeda and Johnson & Johnson, and significant milestone opportunities.

AC Immune SA (NASDAQ: ACIU) on Thursday released interim safety and efficacy results from the Phase 2 VacSYn trial of its anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in early Parkinson's disease.

The results show, for the first time, that targeting a-syn pathology with an active immunotherapy could potentially slow the rate of progression of PD.